| __timestamp | Amphastar Pharmaceuticals, Inc. | BioCryst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 159205000 | 122000 |
| Thursday, January 1, 2015 | 174172000 | 1896000 |
| Friday, January 1, 2016 | 150976000 | 2699000 |
| Sunday, January 1, 2017 | 149380000 | 1702000 |
| Monday, January 1, 2018 | 187681000 | 471000 |
| Tuesday, January 1, 2019 | 190434000 | 4101000 |
| Wednesday, January 1, 2020 | 206506000 | 1676000 |
| Friday, January 1, 2021 | 238029000 | 7264000 |
| Saturday, January 1, 2022 | 250127000 | 6594000 |
| Sunday, January 1, 2023 | 293274000 | 4661000 |
Unveiling the hidden dimensions of data
In the competitive landscape of pharmaceuticals, understanding cost dynamics is crucial. Amphastar Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. have shown distinct trajectories in their cost of revenue from 2014 to 2023. Amphastar's cost of revenue has surged by approximately 84%, from $159 million in 2014 to nearly $293 million in 2023. This growth reflects their expanding operations and market reach. In contrast, BioCryst's cost of revenue, while significantly lower, has seen a more modest increase, peaking at $7.3 million in 2021 before slightly declining to $4.7 million in 2023. This disparity highlights the different scales and strategies of these companies. Amphastar's consistent upward trend suggests robust growth, whereas BioCryst's fluctuations may indicate strategic shifts or market challenges. These insights provide a window into the operational efficiencies and market strategies of these pharmaceutical players.
Cost of Revenue Trends: Pfizer Inc. vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue Trends: Sanofi vs Amphastar Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Bio-Techne Corporation and Amphastar Pharmaceuticals, Inc.'s Expenses
Analyzing Cost of Revenue: Bio-Techne Corporation and BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down Catalent, Inc. and BioCryst Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Grifols, S.A. vs BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down Xenon Pharmaceuticals Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
MorphoSys AG vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for MorphoSys AG and BioCryst Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and Evotec SE
BioCryst Pharmaceuticals, Inc. vs Evotec SE: Efficiency in Cost of Revenue Explored